We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Markers Associated with Autism and MS Investigated

By Labmedica staff writers
Posted on 20 May 2008
Genetic associations with autism and multiple sclerosis are being investigated. More...
It is expected that the resulting information will provide investigators with greater understanding of these diseases, enable more effective use of existing treatments, and development of novel molecular diagnostics and therapies.

Scientists led by Mark Leppert, Ph.D., professor and co-chair of the department of human genetics at the University of Utah (Salt Lake City, UT, USA) are using Affymetrix (Santa Clara, CA, USA) technology and LineaGen's (Salt Lake City, UT, USA) business expertise to generate and analyze genetic information from large multiplex Utah pedigrees, with corresponding decades' worth of longitudinal clinical data.

The Affymetrix Genome-Wide Human single nucleotide polymorphisms (SNP) Array 6.0 will be used to discover the genetic markers. The Affymetrix Genome-Wide Human SNP Array 6.0 features more than 1.8 million markers for genetic variation, including more than 906,600 SNPs and more than 946,000 probes for the detection of copy number variation. The SNP Array 6.0 enables high-performance, high-powered, and low-cost genotyping. The Affymetrix arrays will be run in the lab of Shawn Levy, Ph.D., director of the Vanderbilt Microarray Shared Resource at Vanderbilt University Medical Center (Nashville, TN, USA).

"We chose the Affymetrix SNP Array 6.0 because of its comprehensive genetic content, and its ability to analyze both SNP and copy number variations,” said Dr. Leppert. "We have a valuable and unique genetic population resource at the University of Utah and now we can cost-effectively conduct larger-scale studies to determine the genetic associations of common diseases like MS [multiple sclerosis] and autism.”

The project is being managed and funded by LineaGen, a content-based biomarker discovery company focused on commercializing novel, patentable diagnostic tests that will lead to personalized healthcare regimens.

"The most important metric of a whole-genome association study is the genetic power,” said Kevin King, president of Affymetrix. "The Affymetrix SNP Array 6.0 is the platform for genetic breakthroughs because it combines comprehensive genetic coverage and a cost-effective price per sample. Customers like the University of Utah, Vanderbilt University, and LineaGen are now able to perform higher-powered studies than ever before on diseases that affect millions of people around the world.”


Related Links:
University of Utah
Affymetrix
LineaGen

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.